Collaborators of Mahato's Lab

Dr. Surinder K. Batra

We have collaboration with Dr. Batra’s lab for devising strategies for the treatment of pancreatic cancer. Dr. Batra’s laboratory focuses on defining multifaceted roles of tumor associated antigens (MUC4 and PD2/hPaf1) in the pathogenesis of various types of cancers. The overall goals of our collaboration are to elucidate the molecular mechanisms involved in the proliferation of pancreatic cancer and, to identify miRNAs involved in chemoresistance, and metastasis in human pancreatic cancer tissue specimens. miRNAs are non-coding small ribonucleotides which play a multifunctional role in inducing drug resistance and metastasis in almost any type of cancer.

Dr. Ming-Fong Lin

Dr. Lin is a professor in Biochemistry and Molecular Biology and Eppley Institute for Cancer, UNMC. His lab focuses on the molecular mechanism of cell growth regulation via tyrosine phosphorylation and Redox signal transduction mediating androgen action for understanding mechanism of multi-step carcinogenesis of prostate epithelium. Our collaboration stands on designing the targeted treatments for the prostate cancer.

Dr. Rakesh Singh

Dr. Singh’s research focuses on the mechanism(s) that regulate the process of metastasis which is a highly selective process regulated by interrelated mechanisms. Our collaboration with Dr. Singh brings us his valuable expertise in understanding and thus designing novel therapeutics for targeting metastasis.

Dr. Duane D. Miller

We are working with Professor Duane Miller to design/synthesize novel lipid, polymer and peptide-based carrier molecules for delivery of proteins, oligonucleotides and genes to different disease targets. Dr. Miller is H. S. Van Vleet Professor, Department Chair and Associate Dean, College of Pharmacy, University of Tennessee Health Science Center, Memphis (UTHSC), Memphis. Dr. Miller has extensive experience in designing and synthesis of new drug molecules.

Dr. Wei Li

We are working with Dr. Wei Li to design/synthesize novel polymeric nanoparticles to treat melanoma.  Melanoma is an extremely aggressive type of skin cancer with a high potential of metastasis and ability to develop resistance to most of the known anticancer agents. Metastatic melanoma is associated with poor prognosis and 5 year survival rate of less than 20%.  The goal of this project is to develop novel thiazole analogs which can be used to treat melanoma and enhance their delivery to melanoma tumors using polymeric nanoparticles. Dr. Li has extensive experience in molecular modeling, organic synthesis, in vitro and in vivo biological assays.

Dr. Stephan W. Behrman

Dr. Behrman is a Professor of Surgery in the Department of Surgery at the University of Tennessee Health Science Center, Memphis, TN. Dr. Behrman has an extensive experience in treating pancreatic cancer patients and an abiding interest in understanding the pathophysiology of the disease. His collaboration is valuable to us for the development of tumor models using human pancreatic cancer tissues and their subsequent treatment with the designed formulations.

Jonathan L. Vennerstrom, PhD

We have collaboration with Drs. Jonathan L. Vennerstrom and Yuxiang Dong at college of pharmacy, UNMC, for the discovery and development of new drug candidates against pancreatic cancer. Their research is focused on synthesis of novel therapeutic agents against the parasitic diseases such as malaria, schistosomiasis and trypanosomiasis. In addition, they actively involved in design and synthesis of new anticancer and antibacterial agents. They are also known for the development and optimization of chemical reactions and processes for new drug discovery.

Jean L. Grem, MD

We have active collaboration with Dr. Jean L. Grem, professor of Internal Medicine, Division of Hematology and Oncology, UNMC. She is known nationally as an expert in gastrointestinal malignancies and is currently exploring several novel therapeutic approaches in both colon and pancreatic cancer at UNMC. She is currently the Associate Director for Translational Research of the UNMC Eppley Cancer Center. We are jointly working on cancer experimental therapeutics/early phase clinical trials (PK/PD/PG).